34,455 results match your criteria Prostate Carcinoma


Neuroendocrine Differentiation in the Setting of Prostatic Carcinoma: Contemporary Assessment of a Consecutive Series.

Histopathology 2022 Jun 27. Epub 2022 Jun 27.

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Aim: Clinicopathologic characterization of contemporary series of neuroendocrine (NE) differentiation in the setting of prostatic carcinoma (PCa).

Methods & Results: We reviewed institutional databases for in-house cases with history of PCa and histopathologic evidence of NE differentiation during the disease course. 79 cases identified: 32 primary and 47 metastases. Read More

View Article and Full-Text PDF

WHO Classification of Tumours 5th Edition: Evolving Issues in Classification, Diagnosis and Prognostication of Prostate Cancer.

Histopathology 2022 Jun 27. Epub 2022 Jun 27.

Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada.

The 5 edition of the WHO Classification of Tumours of the Urinary and Male Genital Systems encompasses several updates to the classification and diagnosis of prostatic carcinoma as well as incorporating advancements in assessment of its prognosis, including recent grading modifications. Some of the salient aspects include: 1) recognition that PIN-like carcinoma is not synonymous with a pattern of ductal carcinoma but better classified as a subtype of acinar adenocarcinoma; 2) a specific section on treatment-related neuroendocrine prostatic carcinoma in view of the tight correlation between androgen deprivation therapy and the development of prostatic carcinoma with neuroendocrine morphology, and the emerging data on lineage plasticity; 3) a terminology change of basal cell carcinoma to "adenoid cystic (basal cell) cell carcinoma" given the presence of an underlying MYB::NFIB gene fusion in many cases; 4) discussion of the current issues in the grading of acinar adenocarcinoma and the prognostic significance of cribriform growth patterns; and 5) more detailed coverage of intraductal carcinoma of prostate (IDC-P) reflecting our increased knowledge of this entity, while recommending the descriptive term atypical intraductal proliferation (AIP) for lesions falling short of IDC-P but containing more atypia than typically seen in high-grade prostatic intraepithelial neoplasia (HGPIN). Lesions previously regarded as cribriform patterns of HGPIN are now included in the AIP category. Read More

View Article and Full-Text PDF

Apigenin in Cancer Prevention and Therapy: A Systematic Review and Meta-Analysis of Animal Models.

Crit Rev Oncol Hematol 2022 Jun 22:103751. Epub 2022 Jun 22.

Molecular Cancer Genetics & Translational Research Lab, Section of Genetics, Department of Zoology, Aligarh Muslim University, Aligarh-202002, India. Electronic address:

Background: Apigenin is being increasingly recognized as a cancer chemopreventive agent. We aimed to investigate the anticancer effects of Apigenin in in-vivo studies to know its present research status and how close or how far it is from the clinics.

Methods: Several electronic databases such as PubMed, Springer, Cochrane, and ctri. Read More

View Article and Full-Text PDF

Special issue "The advance of solid tumor research in China": 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma.

Int J Cancer 2022 Jun 25. Epub 2022 Jun 25.

Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, People's Republic of China.

Conventional imaging examinations are not sensitive enough for the early detection of recurrent or metastatic lesions in renal cell carcinoma (RCC) patients. We aimed to explore the role of Ga- prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) in the detection of primary and metastatic lesions in such patients. We retrospectively analyzed 50 RCC patients who underwent Ga-PSMA-11 PET/CT from November 2017 to December 2020. Read More

View Article and Full-Text PDF

Malignancy Diseases in Kidney Transplantation, Clinical Outcomes, Patient, and Allograft Survival: A Case-Control Study.

Transplant Proc 2022 Jun 22. Epub 2022 Jun 22.

Faculty of Medical Sciences, Belo Horizonte, Minas Gerais, Brazil; IMUNOLAB - Laboratory of Histocompatibility, Belo Horizonte, Minas Gerais, Brazil. Electronic address:

Background: Malignancy is a well-known complication in patients after kidney transplantation (KT), but its effect on posttransplant outcomes, allograft, and patient survival remains unexplored. The aim of this study is to report the impact of the comorbidity on clinical outcome, function, and failure of an allograft kidney.

Methods: This case-control study included 101 KT patients. Read More

View Article and Full-Text PDF

Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review.

Curr Opin Urol 2022 Jul;32(4):358-363

Department of Pathology, Medical University of Vienna, Vienna, Austria.

Purpose Of Review: Due to the limited number of cases, there are no guidelines for basal cell carcinoma (BCC) of the prostate. This review combines an unpublished case report of a 55-year-old patient with BCC with an assessment of the latest literature.

Recent Findings: BCC of the prostate has previously been described in only approximately 140 cases. Read More

View Article and Full-Text PDF

Preoperative Platelet Count Correlates With Postoperative Perineural Invasion on Specimen in Patients Treated With Radical Prostatectomy.

Front Oncol 2022 7;12:906936. Epub 2022 Jun 7.

State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Objective: It has been reported that perineural invasion (PNI) after radical prostatectomy (RP) is associated with unfavorable prostate cancer (PCa) prognosis. However, the clinicopathological factors especially hematological parameters that influenced PNI remain unknown. Our aim was to explore the relationship between clinicopathological parameters and PNI in patients who underwent RP. Read More

View Article and Full-Text PDF

A Small Molecule That Promotes Cellular Senescence Prevents Fibrogenesis and Tumorigenesis.

Int J Mol Sci 2022 Jun 20;23(12). Epub 2022 Jun 20.

Osteoneurogen. Inc., Seoul 08501, Korea.

Uncontrolled proliferative diseases, such as fibrosis or cancer, can be fatal. We previously found that a compound containing the chromone scaffold (CS), ONG41008, had potent antifibrogenic effects associated with EMT or cell-cycle control resembling tumorigenesis. We investigated the effects of ONG41008 on tumor cells and compared these effects with those in pathogenic myofibroblasts. Read More

View Article and Full-Text PDF

Characterization of Immune-Based Molecular Subtypes and Prognostic Model in Prostate Adenocarcinoma.

Genes (Basel) 2022 Jun 18;13(6). Epub 2022 Jun 18.

Jiangsu Key Laboratory for Molecular and Medical Biotechnology, School of Life Science, Nanjing Normal University, Nanjing 210023, China.

Prostate adenocarcinoma (PRAD), also named prostate cancer, the most common visceral malignancy, is diagnosed in male individuals. Herein, in order to obtain immune-based subtypes, we performed an integrative analysis to characterize molecular subtypes based on immune-related genes, and further discuss the potential features and differences between identified subtypes. Simultaneously, we also construct an immune-based risk model to assess cancer prognosis. Read More

View Article and Full-Text PDF

Systemic Ablation of Impairs Metastatic Colonization and Improves Insulin Sensitivity in TRAMP Mice: Evidence for Cancer Cell-Extrinsic CAMKK2 Functions in Prostate Cancer.

Cells 2022 06 10;11(12). Epub 2022 Jun 10.

Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.

Despite early studies linking calcium-calmodulin protein kinase kinase 2 (CAMKK2) to prostate cancer cell migration and invasion, the role of CAMKK2 in metastasis in vivo remains unclear. Moreover, while CAMKK2 is known to regulate systemic metabolism, whether CAMKK2's effects on whole-body metabolism would impact prostate cancer progression and/or related comorbidities is not known. Here, we demonstrate that germline ablation of slows, but does not stop, primary prostate tumorigenesis in the TRansgenic Adenocarcinoma Mouse Prostate (TRAMP) genetic mouse model. Read More

View Article and Full-Text PDF

PET-CT in Clinical Adult Oncology-IV. Gynecologic and Genitourinary Malignancies.

Cancers (Basel) 2022 Jun 18;14(12). Epub 2022 Jun 18.

Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA.

Concurrently acquired positron emission tomography and computed tomography (PET-CT) is an advanced imaging modality with diverse oncologic applications, including staging, therapeutic assessment, restaging and longitudinal surveillance. This series of six review articles focuses on providing practical information to providers and imaging professionals regarding the best use and interpretative strategies of PET-CT for oncologic indications in adult patients. In this fourth article of the series, the more common gynecological and adult genitourinary malignancies encountered in clinical practice are addressed, with an emphasis on Food and Drug Administration (FDA)-approved and clinically available radiopharmaceuticals. Read More

View Article and Full-Text PDF

Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules.

Biomedicines 2022 May 31;10(6). Epub 2022 May 31.

Department of Protein Science, KTH Royal Institute of Technology, 114 17 Stockholm, Sweden.

Increasing evidence suggests that therapy targeting the human epidermal growth factor receptor 3 (HER3) could be a viable route for targeted cancer therapy. Here, we studied a novel drug conjugate, Z-ABD-mcDM1, consisting of a HER3-targeting affibody molecule, coupled to the cytotoxic tubulin polymerization inhibitor DM1, and an albumin-binding domain for in vivo half-life extension. Z-ABD-mcDM1 showed a strong affinity to the extracellular domain of HER3 (K 6 nM), and an even stronger affinity (K 0. Read More

View Article and Full-Text PDF

Detection and characterization of latency stage of EBV and histopathological analysis of prostatic adenocarcinoma tissues.

Sci Rep 2022 Jun 21;12(1):10399. Epub 2022 Jun 21.

Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan.

The pathophysiology of prostate cancer involves both genetic and acquired factors, including pathogens, such as viruses. A limited number of studies have shown the presence of Epstein-Barr virus (EBV) in prostate cancer tissues. However, there is a dearth of data exploring EBV latency profile in prostate cancer, and the relationship of EBV with histopathological features of prostate cancer. Read More

View Article and Full-Text PDF

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.

J Clin Oncol 2022 Jun 21:JCO2200868. Epub 2022 Jun 21.

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

Purpose: To provide recommendations for the management of patients with metastatic clear cell renal cell carcinoma (ccRCC).

Methods: An Expert Panel conducted a systematic literature review to obtain evidence to guide treatment recommendations.

Results: The panel considered peer-reviewed reports published in English. Read More

View Article and Full-Text PDF

A Review on Canine and Feline Prostate Pathology.

Front Vet Sci 2022 26;9:881232. Epub 2022 May 26.

School of Veterinary Medicine and Animal Science, Sao-Paulo State University-UNESP, Botucatu, Brazil.

Prostatic diseases are very common in male dogs, accounting for 3-10% of cases submitted to the veterinary practitioners. Commonly reported canine prostatic disorders include prostatic hyperplasia, prostatitis, prostatic cysts and prostatic carcinoma. However, clinical signs may be non-specific, or many cases are asymptomatic, thus leading to a difficult estimation of the actual prevalence of clinical cases. Read More

View Article and Full-Text PDF

FOXP4-AS1 May be a Potential Prognostic Biomarker in Human Cancers: A Meta-Analysis and Bioinformatics Analysis.

Front Oncol 2022 26;12:799265. Epub 2022 May 26.

The First Clinical Medical College of Gansu University of Chinese Medicine (Gansu Provincial Hospital), Lanzhou, China.

Background: Cancer is one of the leading causes of death worldwide. Early diagnosis can significantly lower cancer-related mortality. Studies have shown that the lncRNA Forkhead box P4 antisense RNA 1 (FOXP4-AS1) is aberrantly expressed in various solid tumors. Read More

View Article and Full-Text PDF

Katanin subunits p60 and p80, potential biomarkers for papillary thyroid carcinoma to distinguish nodular goiter: STROBE.

Medicine (Baltimore) 2022 Jun 17;101(24):e29402. Epub 2022 Jun 17.

Institute of Biological Anthropology, Jinzhou Medical University, Jinzhou, Liaoning, China.

Abstract: Katanin subunits p60 and p80 are involved in microtubule-mediated cytoskeletal organization during cell division. Their aberrant expression has been found in prostate, breast, and non-small cell lung (NSCLC) cancers. It has recently been reported that compared with adjacent papillary thyroid carcinoma (PTC) tissues, both are highly expressed in tumor tissues. Read More

View Article and Full-Text PDF

Prostate cancer metastasis mimicking a primary urothelial carcinoma of the bladder.

J Surg Case Rep 2022 Jun 14;2022(6):rjac275. Epub 2022 Jun 14.

Department of Urology, Princess Royal University Hospital, King's College Hospital NHS Foundation Trust Farnborough Common, London BR6 8ND, UK.

We report on a 79-year-old male patient who presented with asymptomatic elevation of prostate-specific antigen and a concurrent papillary lesion, which raised the suspicion of synchronous bladder and prostatic malignancies. He underwent a trans-perineal prostate biopsy as well as transurethral resection of bladder tumour, which revealed a Gleason 9 adenocarcinoma of prostatic origin. While synchronous bladder and prostate cancer is a possibility, differential diagnosis in a patient presenting with lesions of the bladder neck should include advanced prostate cancer. Read More

View Article and Full-Text PDF

The significance of the extent of tissue embedding for the detection of incidental prostate carcinoma on transurethral prostate resection material: the more, the better?

Virchows Arch 2022 Jun 17. Epub 2022 Jun 17.

Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt/Main, Germany.

The aim of this study is to investigate the incidental prostate cancer (iPCa) detection rates of different embedding methods in a large, contemporary cohort of patients with bladder outlet obstruction (BOO) treated with transurethral surgery. We relied on an institutional tertiary-care database to identify BOO patients who underwent either transurethral loop resection or laser (Holmium:yttrium-aluminium garnet) enucleation of the prostate (HoLEP) between 01/2012 and 12/2019. Embedding methods differed with regard to the extent of the additional prostate tissue submitted following the first ten cassettes of primary embedding (cohort A: one [additional] cassette/10 g residual tissue vs. Read More

View Article and Full-Text PDF

Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021.

J Transl Med 2022 Jun 15;20(1):271. Epub 2022 Jun 15.

Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy.

After the success of immunotherapy in the treatment of advanced metastatic cancer, further evaluation in earlier settings, including high-risk, surgically-resectable disease is underway. Potential benefits of a neoadjuvant immunotherapeutic approach include presurgical tumor shrinkage, reduced surgical morbidity, early eradication of micrometastases and prevention of distant disease, and greater antigen-specific T cell response. For some cancers, pathologic response has been established as a surrogate measure for long-term outcomes, therefore offering the ability for early and objective assessment of treatment efficacy and the potential to inform and personalize adjuvant treatment clinical decision-making. Read More

View Article and Full-Text PDF

Real-world experience managing unresectable or metastatic small cell carcinoma of the prostate.

Can Urol Assoc J 2022 Jun 9. Epub 2022 Jun 9.

Department of Medical Oncology, BC Cancer - Victoria, Victoria, BC, Canada.

Introduction: Unresectable and metastatic small cell carcinoma of the prostate (SCPC) is a rare and aggressive disease that is under-represented in clinical trials. We carried out a retrospective chart review of metastatic or unresectable SCPC patients at British Columbia (BC) Cancer centers, studying diagnosis and treatment patterns.

Methods: Drug dispensing records from the six BC Cancer centers were obtained from 2002- 2017. Read More

View Article and Full-Text PDF

Urothelial carcinoma of the prostate with raised β-hCG levels: a case report.

J Med Case Rep 2022 Jun 15;16(1):238. Epub 2022 Jun 15.

Department of Pathology, Chair of Oncology, Medical University of Lodz, ul. Pomorska 251, 90-001, Lodz, Poland.

Background: Trophoblastic differentiation in primary urothelial carcinoma of the prostate is extremely rare. An increased level of β-subunit human chorionic gonadotropin in serum in urothelial carcinoma is detected in approximately 30% of cases. To our knowledge, increased concentration of β-subunit human chorionic gonadotropin in serum in prostatic urothelial carcinoma has never been reported and its clinical significance is not evaluated yet. Read More

View Article and Full-Text PDF

Label-free optical redox ratio from urinary extracellular vesicles as a screening biomarker for bladder cancer.

Am J Cancer Res 2022 15;12(5):2068-2083. Epub 2022 May 15.

Department of Bioengineering, University of Illinois at Urbana-Champaign IL, USA.

Extracellular vesicles (EVs) have been studied for their potential applications in cancer screening, diagnosis, and treatment monitoring. Most studies have focused on the bulk content of EVs; however, it is also informative to investigate their metabolic status, and changes under different physiological and environmental conditions. In this study, noninvasive, multimodal, label-free nonlinear optical microscopy was used to evaluate the optical redox ratio of large EVs (microvesicles) isolated from the urine of 11 dogs in three cohorts (4 healthy, 4 transitional cell carcinoma (TCC) of the bladder, and 3 prostate cancer). Read More

View Article and Full-Text PDF

Imaging response assessment for oncology: An algorithmic approach.

Eur J Radiol Open 2022 7;9:100426. Epub 2022 Jun 7.

Tufts University School of Medicine, United States.

Treatment response assessment by imaging plays a vital role in evaluating changes in solid tumors during oncology therapeutic clinical trials. Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 is the reference standard imaging response criteria and provides details regarding image acquisition, image interpretation and categorical response classification. Read More

View Article and Full-Text PDF

Carbon-ion radiotherapy for urological cancers.

Int J Urol 2022 Jun 12. Epub 2022 Jun 12.

QST Hospital, National Institutes for Quantum Science and Technology, Chiba, Japan.

Carbon-ions are charged particles with a high linear energy transfer, and therefore, they make a better dose distribution with greater biological effects on the tumors compared with photons and protons. Since prostate cancer, renal cell carcinoma, and retroperitoneal sarcomas such as liposarcoma and leiomyosarcoma are known to be radioresistant tumors, carbon-ion radiotherapy, which provides the advantageous radiobiological properties such as an increasing relative biological effectiveness toward the Bragg peak, a reduced oxygen enhancement ratio, and a reduced dependence on fractionation and cell-cycle stage, has been tested for these urological tumors at the National Institute for Radiological Sciences since 1994. To promote carbon-ion radiotherapy as a standard cancer therapy, the Japan Carbon-ion Radiation Oncology Study Group was established in 2015 to create a registry of all treated patients and conduct multi-institutional prospective studies in cooperation with all the Japanese institutes. Read More

View Article and Full-Text PDF

Dosimetric comparison of analytical anisotropic algorithm and the two dose reporting modes of Acuros XB dose calculation algorithm in volumetric modulated arc therapy of carcinoma lung and carcinoma prostate.

Med Dosim 2022 Jun 8. Epub 2022 Jun 8.

SUT Royal Hospital, Ulloor, Thiruvananthapuram, Kerala 695011, India.

Volumetric Modulated Arc Therapy (VMAT) is an important modality for radical radiotherapy of all major treatment sites. This study aims to compare Analytical Anisotropic Algorithm (AAA) and the two dose-reporting modes of Acuros XB (AXB) algorithm -the dose to medium option (D) and the dose to water option (D) in Volumetric Modulated Arc Therapy (VMAT) of carcinoma lung and carcinoma prostate. We also compared the measured dose with Treatment Planning System calculated dose for AAA and the two dose reporting options of Acuros XB using Electronic Portal Imaging Device (EPID) and ArcCHECK phantom. Read More

View Article and Full-Text PDF

A novel biorecognition receptor Citropin-A modified impedimetric biosensor for detection of LNCaP prostate cancer cells.

Anal Biochem 2022 Sep 7;652:114772. Epub 2022 Jun 7.

Ege University, Faculty of Medicine, Department of Medical Biochemistry, Bornova, İzmir, Turkey.

In this study, Citropin-A (Cit-A) as a biorecognition receptor was used for the first time to develop electrochemical impedance spectroscopy (EIS) based biosensor for the detection of Lymph Node Carcinoma of the Prostate (LNCaP) cancer cells. The biosensor was engineered by modification of a gold electrode (AuE) with cysteamine (Cys), Poliamidoamin (PAMAM (G4)) dendrimers, avidin, and biotinylated Cit-A, respectively. The detection time of the LNCaP cells was determined as 300 s by chronoimpedance (CI). Read More

View Article and Full-Text PDF
September 2022

P2 purinergic receptor dysregulation in urologic disease.

Purinergic Signal 2022 Jun 10. Epub 2022 Jun 10.

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

P2 purinergic receptors are involved in the normal function of the kidney, bladder, and prostate via signaling that occurs in response to extracellular nucleotides. Dysregulation of these receptors is common in pathological states and often associated with disease initiation, progression, or aggressiveness. Indeed, P2 purinergic receptor expression is altered across multiple urologic disorders including chronic kidney disease, polycystic kidney disease, interstitial cystitis, urinary incontinence, overactive bladder syndrome, prostatitis, and benign prostatic hyperplasia. Read More

View Article and Full-Text PDF

An Investigation of the Pathology Report of Bladder Cancer Patients with Radical Cystectomy in Southern Iran, 2013-2018: A Cross-Sectional Study.

Med J Islam Repub Iran 2021 27;35. Epub 2021 Dec 27.

Social Determinants of Health Research Center, Health Research Institute, Department of Biostatistics and Epidemiology, School of Medicine, Babol University of Medical Sciences, Babol, Iran.

The oncological outcomes of bladder cancer are directly associated with disease pathology and surgical technique. Therefore, we investigated the pathologic factors of radical cystectomy (RC) specimens. In this retrospective study, 365 patients who underwent RC between March 2013 to March 2018 in hospitals affiliated to Shiraz University were enrolled. Read More

View Article and Full-Text PDF
December 2021